Company intelligence / Profile preview

LimFlow

Paris, Île-de-France, Francelimflow.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

The LimFlow System provides a minimally invasive endovascular solution for patients with end-stage CLTI who have exhausted all other treatment options. The system uses percutaneous deep vein arterialization to bypass blocked arteries and restore blood flow to the ischemic foot. Clinical results from pivotal trials such as PROMISE II demonstrated that the device can save most patients from major amputation, promote wound healing, relieve pain, and improve quality of life. The technology received FDA approval in the US in 2023 after earlier CE Mark approval in Europe

Therapeutic areas: Cardiovascular
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on LimFlow.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LimFlow.

Explore the full profile